Article
PI3K pathway mutations and PTEN levels in primary and metastatic breast cancer.
Molecular cancer therapeutics - 1 Jun 2011
Gonzalez-Angulo Ana M, Ferrer-Lozano Jaime, Stemke-Hale Katherine, Sahin Aysegul, Liu Shuying, Barrera Juan A, Burgues Octavio, Lluch Ana M, Chen Huiqin, Hortobagyi Gabriel N, Mills Gordon B, Meric-Bernstam Funda
Abstract excerpt
The purpose of this work was to determine whether there are differences in PIK3CA mutation status and PTEN protein expression between primary and matched metastatic breast tumors as this could influence patient management. Paraffin sections of 50 μm were used for DNA extraction and slides of 3 μm for immunohistochemistry (IHC) and FISH. Estrogen receptor, progesterone receptor, and HER2 IHC were repeated in a...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
